Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Oct 31, 2025 | (FY)Jul 31, 2025 | (Q4)Jul 31, 2025 | (Q3)Apr 30, 2025 | (Q2)Jan 31, 2025 | (Q1)Oct 31, 2024 | (FY)Jul 31, 2024 | (Q4)Jul 31, 2024 | (Q3)Apr 30, 2024 | (Q2)Jan 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -854.48%-560.67K | -267.84%-1.05M | -289.49%-66.94K | -86.36%-466.62K | -421.22%-458.91K | -438.82%-58.74K | 30.94%-285.78K | -59.83%35.33K | -518.28%-250.4K | 45.34%-88.05K |
| Net income from continuing operations | -299.07%-552.9K | 46.45%-1.24M | 83.52%-304.22K | 7.93%-257.39K | -441.46%-544.81K | -39.53%-138.55K | 75.49%-2.32M | -190.94%-1.85M | 96.30%-279.57K | 88.17%-100.62K |
| Operating gains losses | ---- | --24.6K | ---11.44K | --0 | --0 | --36.04K | ---- | ---- | ---- | ---- |
| Depreciation and amortization | ---- | ---- | ---- | ---- | ---- | ---- | --0 | --0 | ---- | ---- |
| Asset impairment expenditure | ---- | --0 | ---- | ---- | ---- | ---- | -80.02%1.68M | 278.02%1.68M | ---- | ---- |
| Remuneration paid in stock | --145.97K | 3.26%158.28K | --107.53K | --0 | --50.74K | --0 | -37.75%153.28K | --0 | --153.28K | ---- |
| Deferred tax | ---23.48K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other non cashItems | ---90 | 12.20%285 | ---- | ---- | ---- | ---- | 105.35%254 | ---- | ---- | ---- |
| Change In working capital | -397.65%-130.26K | -94.84%10.59K | -29.63%140.9K | -68.60%-209.23K | 179.62%35.16K | -62.48%43.76K | -49.11%205.34K | -23.42%200.23K | -138.07%-124.1K | -59.36%12.57K |
| -Change in receivables | -174.69%-19.18K | 215.30%18.9K | 671.07%28.43K | -191.95%-10.15K | -5,559.48%-25.06K | 406.08%25.68K | -117.59%-16.39K | -104.63%-4.98K | -105.92%-3.48K | 101.88%459 |
| -Change in prepaid assets | 18.34%-15.84K | -145.69%-14.57K | -121.45%-10.2K | 146.13%9.94K | 166.67%5.09K | -243.48%-19.4K | 707.72%31.89K | 5,125.38%47.55K | -283.81%-21.55K | -122.99%-7.64K |
| -Change in payables and accrued expense | -354.06%-95.24K | -96.70%6.26K | -22.19%122.67K | -110.97%-209.02K | 179.02%55.12K | -66.38%37.49K | -39.84%189.84K | 3.04%157.66K | -138.79%-99.08K | -10.89%19.76K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -854.63%-560.76K | -267.84%-1.05M | -289.49%-66.94K | -86.36%-466.62K | -421.22%-458.91K | -438.82%-58.74K | 30.94%-285.78K | -59.83%35.33K | -518.28%-250.4K | 45.34%-88.05K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -464.55K | -4,109.66%-447.96K | -524.12%-290.31K | -193.97%-38.68K | -223.48%-118.97K | 0 | 100.93%11.17K | 60.06%-46.52K | 84.97%-13.16K | 134.42%96.35K |
| Net PPE purchase and sale | ---- | -1,529.96%-159.76K | 95.47%-2.11K | -193.97%-38.68K | -223.48%-118.97K | --0 | 100.94%11.17K | 63.10%-46.52K | 85.15%-13.16K | 135.77%96.35K |
| Net other investing changes | ---464.55K | ---288.2K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---464.55K | -4,109.66%-447.96K | -524.12%-290.31K | -193.97%-38.68K | -223.48%-118.97K | --0 | 100.93%11.17K | 60.06%-46.52K | 84.97%-13.16K | 134.42%96.35K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 30.94%345.68K | 922.26%2.76M | 3,782.36%368.82K | 579.30%1.6M | 2,509.88%528.5K | 5,457.96%264K | 158.00%270.28K | 9.5K | 84,308.21%235.78K | -80.72%20.25K |
| Net issuance payments of debt | --0 | -158.31%-5.54K | -103.00%-285 | --0 | --0 | -210.61%-5.25K | --9.5K | --9.5K | --0 | ---4.75K |
| Net common stock issuance | -6.60%252.18K | 928.00%2.7M | --274.47K | 540.20%1.68M | --475K | --270K | 145.69%262.88K | --0 | --262.88K | --0 |
| Proceeds from stock option exercised by employees | --93.5K | --167.15K | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Net other financing activities | ---- | -4,712.48%-101.06K | ---72.51K | -200.03%-81.31K | --53.5K | ---743 | 6.25%-2.1K | --0 | -9,578.57%-27.1K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 30.94%345.68K | 922.26%2.76M | 3,782.36%368.82K | 579.30%1.6M | 2,509.88%528.5K | 5,457.96%264K | 158.00%270.28K | --9.5K | 84,308.21%235.78K | -80.72%20.25K |
| Net cash flow | ||||||||||
| Beginning cash position | 32,141.96%1.27M | -52.37%3.93K | 22,248.00%1.26M | 378.61%159.81K | 4,220.40%209.19K | -52.37%3.93K | -99.46%8.26K | -84.72%5.62K | -48.45%33.39K | -98.79%4.84K |
| Current changes in cash | -431.11%-679.64K | 29,334.86%1.26M | 785.26%11.57K | 4,048.03%1.1M | -272.97%-49.38K | 6,114.12%205.26K | 99.71%-4.32K | 94.08%-1.69K | 0.79%-27.77K | 108.50%28.55K |
| End cash Position | 181.14%588.12K | 32,141.99%1.27M | 32,141.99%1.27M | 22,248.00%1.26M | 378.61%159.81K | 4,220.40%209.19K | -52.37%3.93K | -52.37%3.93K | -84.72%5.62K | -48.45%33.39K |
| Free cash from | -854.63%-560.76K | -207.26%-1.21M | -517.09%-69.05K | -91.73%-505.31K | -419.58%-577.88K | -619.60%-58.74K | 75.42%-394.13K | 70.63%-11.19K | -817.54%-263.55K | 74.16%-111.22K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.